Figure 6.
HDAC11KO T cells have enhanced antitumor efficacy in vivo. C57BL/6 mice were subcutaneously injected with 2.2 × 106 FCmuMCL1 cells on day 0. On day 4, 4 mice per group received adoptive transfer of WT T cells (squares), HDAC11KO T cells (triangles), or no adoptive transfer (circles). Group tumor volumes with standard deviations are graphed. Results shown are representative of 2 independent experiments. **P < .01; ***P < .001. ACT, adoptive cell therapy; MCL, mantle-cell lymphoma.
